Myocarditis following COVID-19 mRNA vaccination
Open accessAbstract
Background Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination.Methods Patients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. In all study patients, we excluded past and current COVID-19. Routine clinical and laboratory investigations for common etiologies of myocarditis were performed. Laboratory tests also included troponin and C-reactive protein levels. The diagnosis of myocarditis was established after cardiac MRI.Findings Five patients presented after the second and one after the first dose of the vaccine. All patients were males with a median age of 23 years. Myocarditis was diagnosed in all patients, there was no evidence of COVID-19 infection. Laboratory assays excluded concomitant infection; autoimmune disorder was considered unlikely. All patients responded to the BNT162b2 vaccine. The clinical course was mild in all six patients.Interpretation Our report of myocarditis after BNT162b2 vaccination may be possibly considered as an adverse reaction following immunization. We believe our information should be interpreted with caution and further surveillance is warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple cases of myocarditis after Covid-19 vaccination have recently been reported in the literature.
“multiple cases of myocarditis after Covid-19 vaccination have recently been reported in the literature,21-25”
From Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3× · see citing works
“In the clinical trials, systemic adverse reactions after the second dose were reported more frequently mainly in the younger population with a median onset time of 1–2 days [1,2].”
BackgroundMethodmRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation
Ferreira, V. M., Schulz-Menger, J., Holmvang, G., Kramer, C. M., Carbone, I., Sechtem, U., Kindermann, I., Gutberlet, M., Cooper, L. T., Liu, P., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.072 · Cited by 2,059 · see citing works
Siripanthong, B., Nazarian, S., Muser, D., Deo, R., Santangeli, P., Khanji, M. Y., Cooper, L. T., & Chahal, C. A. A. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.001 · Cited by 789 · see citing works
Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M. M., Curran, K. G., Chamberland, M. E., McClung, N. M., Campos-Outcalt, D. E., Morgan, R. L., Mbaeyi, S. A., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e2 · Cited by 536 · see citing works
COVID-19: Characteristics and Therapeutics
Chilamakuri, R., & Agarwal, S. (2021) · Cells · doi:10.3390/cells10020206 · Cited by 283 · see citing works
Caforio, A. L. P., Adler, Y., Agostini, C., Allanore, Y., Anastasakis, A., Arad, M., Böhm, M., Charron, P., Elliot, P. M., Eriksson, U., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx321 · Cited by 264 · see citing works
Smallpox vaccination and myopericarditis: a clinical review
Cassimatis, D. C., Atwood, J. E., Engler, R. M., Linz, P. E., Grabenstein, J. D., & Vernalis, M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.053 · Cited by 187 · see citing works
Eckart, R. E., Love, S. S., Atwood, J. E., Arness, M. K., Cassimatis, D. C., Campbell, C. L., Boyd, S. Y., Murphy, J. G., Swerdlow, D. L., Collins, L. C., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.05.004 · Cited by 178 · see citing works
Engler, R. J. M., Nelson, M. R., Collins Jr., L. C., Spooner, C., Hemann, B. A., Gibbs, B. T., Atwood, J. E., Howard, R. S., Chang, A. S., Cruser, D. L., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118283 · Cited by 169 · see citing works
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018
Su, J. R., McNeil, M. M., Welsh, K. J., Marquez, P. L., Ng, C. S., Yan, M., & Cano, M. V. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.12.046 · Cited by 143 · see citing works
Mei, R., Raschi, E., Forcesi, E., Diemberger, I., Ponti, F. D., & Poluzzi, E. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.054 · Cited by 84 · see citing works
Myocarditis and pericarditis are rare following live viral vaccinations in adults
Kuntz, J. L., Crane, B., Weinmann, S. A., & Naleway, A. L. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.030 · Cited by 64 · see citing works
Researchers Investigate What COVID-19 Does to the Heart
Abbasi, J. (2021) · JAMA · doi:10.1001/jama.2021.0107 · Cited by 46 · see citing works
Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel
Faix, D. J., Gordon, D. M., Perry, L. N., Raymond-Loher, I., Tati, N., Lin, G., DiPietro, G., Selmani, A., & Decker, M. D. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.037 · Cited by 26 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [2]Walsh E.E. Frenck R.W. Jr. Falsey A.R. Kitchin N. Absalon J. Gurtman A. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates N Engl J Med 383 2020 2439 2450 33053279 PMC7583697
Cited by
Sorted by citations
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027 · see citing works
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678 · see citing works
Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
Mansanguan, S., Charunwatthana, P., Piyaphanee, W., Dechkhajorn, W., Poolcharoen, A., & Mansanguan, C. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7080196 · Cited by 83 · see citing works
- Authors
- Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., Zoabi, M., Aisman, M., Goldschmid, N., & Berar Yanay, N.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Hillel Yaffe Medical Center (IL)
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 39
- Issue
- 29
- Pages
- 3790-3793
- ISSN
- 0264-410X (ISSN-L)
- PMC
- PMC8162819
- OpenAlex
- W3166407960
- Cited by
- 274
- References
- 16
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 17 · 2023: 41 · 2022: 117 · 2021: 82
- FWCI
- 43.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Vaccine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- myocarditis, COVID-19 mRNA vaccine, BNT162b2, vaccine adverse events, vaccine safety, young men, chest pain
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adult, Humans, Male, Myocarditis, RNA, Messenger, Vaccination, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
